Analyst Reco. Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Equities

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 16/01/2026			5-day change	1st Jan Change
61.94 ^CNY	-1.95%		-2.61%	+3.98%

01-13	Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug	MT
01-13	Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation	MT

Analyst Reco.

08/09/25	Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 78.21 Yuan From 66.66 Yuan, Keeps at Buy	MT
08/09/25	Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$94.54 From HK$80.57, Keeps at Buy	MT
22/08/25	Jefferies Adjusts Jiangsu Hengrui Medicine's Price Target to 86 Yuan From 80 Yuan, Keeps at Buy	MT
29/07/25	Nomura Upgrades Jiangsu Hengrui Medicine to Buy From Neutral, Adjusts Price Target to 66.66 Yuan From 59.15 Yuan	MT
29/07/25	Nomura Upgrades Jiangsu Hengrui Pharmaceuticals to Buy From Neutral, Adjusts Price Target to HK$80.57 From HK$71.50	MT
17/07/25	Nomura Starts Jiangsu Hengrui Pharmaceuticals at Neutral With HK$71.50 Price Target	MT
17/07/25	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 59.15 Yuan From 53.45 Yuan, Keeps at Neutral	MT
03/04/25	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 80 Yuan From 60 Yuan, Keeps at Buy	MT
31/03/25	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 53.45 Yuan From 51.31 Yuan, Keeps at Neutral	MT
26/02/25	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 51.31 Yuan From 50.17 Yuan, Keeps at Neutral	MT
13/01/25	Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 Mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531	CI
27/11/24	SPDB International HK Starts Jiangsu Hengrui Pharmaceuticals at Buy with 61 Yuan Price Target	MT
22/10/24	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 50.17 Yuan From 48.32 Yuan, Keeps at Neutral	MT
23/07/24	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 48.32 Yuan From 51.12 Yuan, Keeps at Neutral	MT
15/03/24	Nomura Adjusts Jiangsu Hengrui Medicine’s Price Target to 51.12 Yuan From 49.24 Yuan, Keeps at Neutral	MT
17/10/23	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 49.24 Yuan From 50.19 Yuan, Keeps at Neutral	MT
25/07/23	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 50.19 Yuan From 46.30 Yuan, Keeps at Neutral	MT
24/04/23	Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 46.30 Yuan From 41.29 Yuan, Keeps at Neutral	MT
09/03/23	Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 41.29 Yuan From 38.29 Yuan, Keeps at Neutral	MT
22/08/22	Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 34.13 Yuan From 31.71 Yuan, Keeps at Neutral	MT
25/04/22	Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to 31.71 Yuan From 55.66 Yuan, Keeps at Neutral	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Analyst Reco. Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Equities

600276

CNE0000014W7

Pharmaceuticals

Analyst Reco.

Filters